{"id":5179,"date":"2017-10-04T12:23:03","date_gmt":"2017-10-04T10:23:03","guid":{"rendered":"https:\/\/www.sequanamedical.com\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\/"},"modified":"2022-07-07T14:29:59","modified_gmt":"2022-07-07T12:29:59","slug":"sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt","status":"publish","type":"post","link":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\/","title":{"rendered":"Sequana Medical Announces Publication of Results of alfapump\u00ae Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology &#038; Therapeutics (AP&#038;T)."},"content":{"rendered":"<p>Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of \u201cTreatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis\u201d, the results of the first 56 patients in the <strong>alfa<\/strong>pump\u00ae multicentre Post-Marketing Surveillance Registry (PMSR) in AP&#038;T (Alimentary Pharmacology &#038; Therapeutics) (<a href=\"http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.14331\/epdf\" target=\"_blank\" rel=\"noopener\">Publication details<\/a>).  <\/p>\n<p>In the largest reported series to-date of patients implanted with the <strong>alfa<\/strong>pump\u00ae, the continuous drainage of ascites with the <strong>alfa<\/strong>pump\u00ae led to a significant reduction in paracentesis frequency, with the median frequency of paracentesis dropped over 90%, from 2.17 to 0.17 per month.<\/p>\n<p>Fifty-six <strong>alfa<\/strong>pump\u00ae patients (43 males, 13 women; mean age 62 years) with a contraindication to TIPSS (transjugular intrahepatic portosystemic shunt), from centres in Germany, Switzerland, UK and Spain were followed for up to 24 months. Complications, device deficiencies, paracentesis frequency and patient survival were recorded. <\/p>\n<p>Dr. Guido Stirnimann of University Hospital Inselspital Bern, Switzerland, lead author of the manuscript, commented \u201cThe management of refractory ascites in patients with cirrhosis is challenging and novel therapies are an unmet need in Hepatology, due to the important limitations of both large volume paracentesis and TIPSS.  The results of this largest reported series to-date of <strong>alfa<\/strong>pump\u00ae patients, demonstrates that in real life subjects <strong>alfa<\/strong>pump\u00ae provides an innovative and effective treatment option.\u201d<\/p>\n<p>\u201cWe are very pleased the results from the post-marketing surveillance registry has clearly demonstrated that the <strong>alfa<\/strong>pump\u00ae delivers important benefits with this key complication of liver disease\u201d said Ian Crosbie, Chief Executive Officer of Sequana Medical. \u201cThrough our ongoing development work and close collaboration with clinicians, we continue to further improve the performance of the <strong>alfa<\/strong>pump\u00ae.  We are already seeing the impact of this in our more recent patient implants where we are seeing much lower rates of adverse events and reinterventions, and even greater reductions in paracentesis frequency.\u201d<\/p>\n<p>Download the full <a href=\"\/wp-content\/uploads\/2017\/10\/PMSR-English-Final-Press-release.pdf\">press release<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of \u201cTreatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis\u201d, the results of the first 56 patients in the alfapump\u00ae multicentre Post-Marketing Surveillance Registry (PMSR) in AP&#038;T [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[74],"tags":[94],"class_list":["post-5179","post","type-post","status-publish","format-standard","hentry","category-persberichten","tag-niet-gereglementeerd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sequana Medical Announces Publication of Results of alfapump\u00ae Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology &amp; Therapeutics (AP&amp;T). - Sequana Medical<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sequana Medical Announces Publication of Results of alfapump\u00ae Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology &amp; Therapeutics (AP&amp;T). - Sequana Medical\" \/>\n<meta property=\"og:description\" content=\"Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of \u201cTreatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis\u201d, the results of the first 56 patients in the alfapump\u00ae multicentre Post-Marketing Surveillance Registry (PMSR) in AP&#038;T [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\/\" \/>\n<meta property=\"og:site_name\" content=\"Sequana Medical\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/alfapump\" \/>\n<meta property=\"article:published_time\" content=\"2017-10-04T10:23:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-07T12:29:59+00:00\" \/>\n<meta name=\"author\" content=\"luca\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@SequanaMed\" \/>\n<meta name=\"twitter:site\" content=\"@SequanaMed\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\\\/\"},\"author\":{\"name\":\"luca\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/person\\\/a2c1f689fbb4e32a5d100b1fea0ea29a\"},\"headline\":\"Sequana Medical Announces Publication of Results of alfapump\u00ae Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology &#038; Therapeutics (AP&#038;T).\",\"datePublished\":\"2017-10-04T10:23:03+00:00\",\"dateModified\":\"2022-07-07T12:29:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\\\/\"},\"wordCount\":325,\"publisher\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\"},\"keywords\":[\"Niet-gereglementeerd\"],\"articleSection\":[\"Persberichten\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\\\/\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\\\/\",\"name\":\"Sequana Medical Announces Publication of Results of alfapump\u00ae Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology & Therapeutics (AP&T). - Sequana Medical\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#website\"},\"datePublished\":\"2017-10-04T10:23:03+00:00\",\"dateModified\":\"2022-07-07T12:29:59+00:00\",\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#website\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/\",\"name\":\"Sequana Medical\",\"description\":\"Pioneer in the treatment of fluid overload\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sequanamedical.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\",\"name\":\"Sequana Medical NV\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/Sequana-medical_logo.png\",\"contentUrl\":\"https:\\\/\\\/www.sequanamedical.com\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/Sequana-medical_logo.png\",\"width\":396,\"height\":70,\"caption\":\"Sequana Medical NV\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/alfapump\",\"https:\\\/\\\/x.com\\\/SequanaMed\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/sequana-medical\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/person\\\/a2c1f689fbb4e32a5d100b1fea0ea29a\",\"name\":\"luca\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/81c56a50392cc3ed4a33ad59f4984322da300d360b064ba23228383ec60d9d37?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/81c56a50392cc3ed4a33ad59f4984322da300d360b064ba23228383ec60d9d37?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/81c56a50392cc3ed4a33ad59f4984322da300d360b064ba23228383ec60d9d37?s=96&d=mm&r=g\",\"caption\":\"luca\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sequana Medical Announces Publication of Results of alfapump\u00ae Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology & Therapeutics (AP&T). - Sequana Medical","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\/","og_locale":"nl_NL","og_type":"article","og_title":"Sequana Medical Announces Publication of Results of alfapump\u00ae Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology & Therapeutics (AP&T). - Sequana Medical","og_description":"Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of \u201cTreatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis\u201d, the results of the first 56 patients in the alfapump\u00ae multicentre Post-Marketing Surveillance Registry (PMSR) in AP&#038;T [&hellip;]","og_url":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\/","og_site_name":"Sequana Medical","article_publisher":"https:\/\/www.facebook.com\/alfapump","article_published_time":"2017-10-04T10:23:03+00:00","article_modified_time":"2022-07-07T12:29:59+00:00","author":"luca","twitter_card":"summary_large_image","twitter_creator":"@SequanaMed","twitter_site":"@SequanaMed","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\/#article","isPartOf":{"@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\/"},"author":{"name":"luca","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/person\/a2c1f689fbb4e32a5d100b1fea0ea29a"},"headline":"Sequana Medical Announces Publication of Results of alfapump\u00ae Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology &#038; Therapeutics (AP&#038;T).","datePublished":"2017-10-04T10:23:03+00:00","dateModified":"2022-07-07T12:29:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\/"},"wordCount":325,"publisher":{"@id":"https:\/\/www.sequanamedical.com\/#organization"},"keywords":["Niet-gereglementeerd"],"articleSection":["Persberichten"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\/","url":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\/","name":"Sequana Medical Announces Publication of Results of alfapump\u00ae Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology & Therapeutics (AP&T). - Sequana Medical","isPartOf":{"@id":"https:\/\/www.sequanamedical.com\/#website"},"datePublished":"2017-10-04T10:23:03+00:00","dateModified":"2022-07-07T12:29:59+00:00","inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-announces-publication-results-alfapump-multicentre-post-marketing-surveillance-registry-alimentary-pharmacology-therapeutics-apt\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.sequanamedical.com\/#website","url":"https:\/\/www.sequanamedical.com\/","name":"Sequana Medical","description":"Pioneer in the treatment of fluid overload","publisher":{"@id":"https:\/\/www.sequanamedical.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sequanamedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.sequanamedical.com\/#organization","name":"Sequana Medical NV","url":"https:\/\/www.sequanamedical.com\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.sequanamedical.com\/wp-content\/uploads\/2017\/09\/Sequana-medical_logo.png","contentUrl":"https:\/\/www.sequanamedical.com\/wp-content\/uploads\/2017\/09\/Sequana-medical_logo.png","width":396,"height":70,"caption":"Sequana Medical NV"},"image":{"@id":"https:\/\/www.sequanamedical.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/alfapump","https:\/\/x.com\/SequanaMed","https:\/\/www.linkedin.com\/company\/sequana-medical"]},{"@type":"Person","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/person\/a2c1f689fbb4e32a5d100b1fea0ea29a","name":"luca","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/secure.gravatar.com\/avatar\/81c56a50392cc3ed4a33ad59f4984322da300d360b064ba23228383ec60d9d37?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/81c56a50392cc3ed4a33ad59f4984322da300d360b064ba23228383ec60d9d37?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/81c56a50392cc3ed4a33ad59f4984322da300d360b064ba23228383ec60d9d37?s=96&d=mm&r=g","caption":"luca"}}]}},"_links":{"self":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts\/5179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/comments?post=5179"}],"version-history":[{"count":0,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts\/5179\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/media?parent=5179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/categories?post=5179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/tags?post=5179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}